AI & ChatGPT searches , social queriess for EGFR
Search references for EGFR. Phrases containing EGFR
See searches and references containing EGFR!
Search references for EGFR. Phrases containing EGFR
See searches and references containing EGFR!EGFR
Topics referred to by the same term
EGFR may refer to: Epidermal growth factor receptor (EGFR), a transmembrane receptor protein in humans Estimated glomerular filtration rate (eGFR), a
EGFR
Transmembrane protein
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor
Epidermal growth factor receptor
Epidermal_growth_factor_receptor
Protein found in Drosophila melanogaster
epidermal growth factor receptor (EGFR) pathway in Drosophila melanogaster. Argos inhibits the EGFR pathway by sequestering the EGFR ligand Spitz. Argos binds
Argos_(EGFR_Inhibitor)
Non-coding RNA in the species Homo sapiens
EGFR antisense RNA 1 is a protein that in humans is encoded by the EGFR-AS1 gene. GRCh38: Ensembl release 89: ENSG00000224057 – Ensembl, May 2017 "Human
EGFR-AS1
Medication used for cancer
cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore
Gefitinib
Renal function test
blood and urine, or estimated by formulas using just a blood test result (eGFR and eCCr). The results of these tests are used to assess the excretory function
Glomerular_filtration_rate
Any type of epithelial lung cancer other than small-cell lung carcinoma
and EGFR activating mutations are typically mutually exclusive. Thus, patients who fail crizotinib are not recommended to be switched to an EGFR-targeted
Non-small-cell_lung_cancer
Aggressive type of brain cancer
copies of the epidermal growth factor receptor (EGFR) gene, and most have higher than normal expression of EGFR, whereas the gene TP53 (p53), which is often
Glioblastoma
Drug for treatment of cancer
growth factor receptor (EGFR) tyrosine kinase inhibitor. In China, aumolertinib is approved for the treatment of people with EGFR T790M mutation—positive
Aumolertinib
Family of proteins
the epidermal growth factor receptor (EGFR), its first discovered member. In humans, the family includes Her1 (EGFR, ErbB1), Her2 (ErbB2), Her3 (ErbB3)
ErbB
Monoclonal antibody
have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The most common side effects include rash,
Amivantamab
Chemical compound, used as a medication to treat lung cancer
coding for EGFR or for activating EGFR mutations. The T790M mutation may be de novo or acquired following first-line treatment with other EGFR tyrosine
Osimertinib
Pharmaceutical drug
sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer
Cetuximab
Medication for treatment of non-small-cell lung cancer
is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) — either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation
Erlotinib
Chemical compound
of NSCLC that harbour mutations in the epidermal growth factor receptor (EGFR) gene. Afatinib is a therapeutic alternative on the World Health Organization's
Afatinib
Monoclonal antibody
trade name HuMax-EGFR) is a fully human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFR). It is a product
Zalutumumab
Pharmaceutical drug
of non-small-cell lung cancer. It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Sunvozertinib was approved for medical use in
Sunvozertinib
Cell signaling pathway
factor receptor (EGFR), are activated by extracellular ligands, such as the epidermal growth factor (EGF). Binding of EGF to the EGFR activates the tyrosine
MAPK/ERK_pathway
ALK inhibitor for treatment of non-small-cell lung cancer
kinase anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), as well as several nonreceptor tyrosine kinases such as FAK, FAK2, and
Brigatinib
Chemical compound
Nimotuzumab (h-R3, BIOMAb EGFR, Biocon, India; TheraCIM, CIMYM Biosciences, Canada; Theraloc, Oncoscience, Europe, CIMAher, Center of Molecular Immunology
Nimotuzumab
Small molecule tyrosine kinase inhibitor
a covalent bond with the cysteine 797 in the EGFR active site, leading to sustained inhibition of EGFR enzymatic activity. The irreversible binding leads
Mobocertinib
Pharmaceutical drug
specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans). Panitumumab is manufactured by Amgen and was
Panitumumab
Genetic variant
receptor (EGFR). The mutation substitutes a threonine (T) with a methionine (M) at position 790 of exon 20, affecting the ATP binding pocket of the EGFR kinase
T790M
Disease that causes scarring of the lungs
pulmonary fibrosis. EGFR is a transmembrane receptor that plays a role in cellular proliferation, differentiation, and survival. Dysregulated EGFR signaling has
Pulmonary_fibrosis
Protein-coding gene in humans
mutation in the epidermal growth factor receptor (EGFR) will predict how patients will respond to certain EGFR antagonists such as erlotinib (Tarceva) or gefitinib
KRAS
Drosophila melanogaster gene
expression of rhomboid (rho) with Serrate-Notch signaling, which activates the EGFR signaling pathway. The drosophila EGF receptor (DER) is responsible for activating
Shavenbaby
Medical condition
receptor (EGFR) has been reported in a majority of epithelioid sarcomas. EGFR is a member of the HER receptor family. Upon ligand binding, EGFR phosphorylation
Epithelioid_sarcoma
Medication
It contains amivantamab, a bispecific epidermal growth factor receptor (EGFR)-directed and hepatocyte growth factor receptor (MET)-directed antibody;
Amivantamab/hyaluronidase
Biological process in primates
Jak/Stat. Based on research with epidermal growth factor receptor (EGFR) knockout mice, the EGFR, which is the molecular target of EGF, TGF-α, amphiregulin,
Breast_development
Chemical compound
being evaluated for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, particularly exon 20 insertion mutations. "Zipalertinib - Cullinan
Zipalertinib
Oncologist and physician-scientist
angiogenesis, and biomarker development in lung cancer, including KRAS‑mutant and EGFR‑mutant non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
John_V._Heymach
Range of practices that support skin integrity, health, and appearance
controversial but is now recommended for practice. Epidermal growth factor receptor (EGFR) inhibitors are medications used in cancer treatment. These medications commonly
Skin_care
Pharmaceutical compound
for the treatment of cancer. It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with antineoplastic properties. Developed
Asandeutertinib
Chemical compound
inhibitor (EGFR-TKI). Icotinib is approved for use in China as first-line monotherapy in patients with non-small-cell lung cancer with somatic EGFR mutations
Icotinib
Human gene
EGFR-coamplified and overexpressed protein, also known as ECOP, is a human gene. ECOP is a human protein coded by this gene found on chromosome 7p11.2
ECOP
of kinases like human epidermal growth factor receptor 2 (HER2) from the EGFR family. Mutations often occur in the HER2 gene upon treatment with an inhibitor
Antineoplastic_resistance
Autobiographical book by Paul Kalanithi
neuroscience. In May 2013, he was diagnosed with stage-4 non-small-cell EGFR-positive lung cancer. As Kalanithi underwent cancer treatment, he shared
When_Breath_Becomes_Air
Breakdown product of creatine phosphate
function is given by calculating the estimated glomerular filtration rate (eGFR). eGFR can be calculated without a 24-hour urine collection, using serum creatinine
Creatinine
Topics referred to by the same term
Argos (Stargate), a fictional planet in the Stargate SG-1 universe Argos (EGFR Inhibitor), a protein in Drosophila melanogaster ARGOS (optics system), a
Argos
Indian multinational biopharmaceutical company
brands in India include INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Evertor
Biocon
Lung cancer of glandular origin or characteristics
genes, including TP53 (mutated in 46% of cases), EGFR (27%), KRAS (32%), KEAP1, STK11 and NF1. EGFR and KRAS mutations tend to appear in a mutually exclusive
Adenocarcinoma_of_the_lung
Mammalian protein found in humans
340). HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. But contrary to other members of the ERBB family, HER2 does
HER2
Chemical compound
nepidermin is an agonist of the epidermal growth factor receptor (EGFR), and is the first EGFR agonist to be marketed. It was developed by Cuban Center for
Nepidermin
Chemical compound
tumors caused by mutations of EGFR. The binding of erlotinib to the ATP-binding sites of the EGFR receptors prevents EGFR from producing phosphotyrosine
Quinazoline
Cancer medication
inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is used in combination therapy for HER2-positive breast cancer
Lapatinib
Protein that stimulates cell division and differentiation
that stimulates cell growth and differentiation by binding to its receptor, EGFR. Human EGF is 6-kDa and has 53 amino acid residues and three intramolecular
Epidermal_growth_factor
Class of pharmaceutical drugs
crizotinib. Ariad's and Takeda's brigatinib (also an inhibitor of mutated EGFR) was the latest second-generation inhibitor and was approved in April 2017
ALK_inhibitor
Abnormal kidney structure or gradual loss of kidney function
Diagnosis is by blood tests to measure the estimated glomerular filtration rate (eGFR), and a urine test to measure albumin. Ultrasound or kidney biopsy may be
Chronic_kidney_disease
Drug typically used in cancer treatment
inhibiting the catalytic activity of the epidermal growth factor receptor (EGFR). The 1988 study was the first demonstration of a systematic search and discovery
Tyrosine_kinase_inhibitor
Protein-coding gene in humans
adaptor proteins transmit signaling of the cell surface receptors such as EGFR, erbV-2 and insulin receptors. p52SHC and p46SHC activate the Ras-ERK pathway
SHC1
Protein-tyrosine kinase family of enzymes
Tyr845 in the catalytic domain of EGFR is not auto-phosphorylated. Later, it requires an association of c-Src with EGFR as well as the kinase activity of
Src_family_kinase
Class of enzymes
transduction pathways. The ErbB protein family or epidermal growth factor receptor (EGFR) family is a family of four structurally related receptor tyrosine kinases
Receptor_tyrosine_kinase
Diabetes medication
in adults with heart failure; to reduce the risk of sustained decline in eGFR in chronic kidney disease, hospitalization in adults with chronic kidney
Empagliflozin
Pharmaceutical drug used in cancer treatment
EGFR or in ALK; if chemotherapy has already been administered, then pembrolizumab can be used as a second-line treatment, but if the cancer has EGFR or
Pembrolizumab
Antibodies from clones of the same blood cell
other indications underway EGFR inhibitor humanized cetuximab approved in squamous cell carcinomas, colorectal carcinoma EGFR inhibitor chimeric sasanlimab
Monoclonal_antibody
Anti-cancer medication
participants with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations. The trial was
Lazertinib
forming than seen with EGFR active. When EGFR is active, CSPG functioned normally, restricting neurogenesis. Drugs manipulating EGFR may be helpful in preventing
Chondroitin sulfate proteoglycan
Chondroitin_sulfate_proteoglycan
Disease where the kidneys fail to adequately filter waste products from the blood
according to the estimated glomerular filtration rate (eGFR). In CKD1, eGFR is normal and in CKD5 eGFR has decreased to less than 15 ml/min. Acute kidney
Kidney_failure
Vacuole to which materials ingested by endocytosis are delivered
lysosomes. EGF remains bound to the EGF receptor (EGFR) once it is endocytosed to endosomes. The activated EGFRs stimulate their own ubiquitination, and this
Endosome
Protein found in humans
the ERBB3 gene. ErbB3 is a member of the epidermal growth factor receptor (EGFR/ERBB) family of receptor tyrosine kinases. The kinase-impaired ErbB3 is known
ERBB3
Substance or process that is indicative of the presence of cancer in the body
CA-125 (ovarian cancer), CA19.9 (pancreatic cancer), CEA (colorectal cancer), EGFR (Non-small-cell lung carcinoma), HER-2 (Breast Cancer), KIT (gastrointestinal
Cancer_biomarker
Chemical compound
inhibitor with IC50 of 2, 6, 77, 59 nM for EGFR, ErbB2, KDR, and Flt-1. In cells, growth factor-induced EGFR and ErbB2 phosphorylation was also efficiently
AEE788
Protein-coding gene in the species Homo sapiens
gene. NRG1 is one of four proteins in the neuregulin family that act on the EGFR family of receptors. Neuregulin 1 is produced in numerous isoforms by alternative
Neuregulin_1
Medical condition
exposure to tobacco smoke. Non-smokers with AIS commonly have mutations in EGFR (a driver) or HER2 (an important oncogene), or a gene fusion with ALK or
Adenocarcinoma in situ of the lung
Adenocarcinoma_in_situ_of_the_lung
Vaccine used to treat cancer
to potentiate the immune response. The epidermal growth factor receptor (EGFR) is hijacked by many types of cancer, including cancers of the lung, colon
CimaVax-EGF
Malignant tumor characterized by uncontrolled cell growth in lung tissue
of tumors have mutations in the EGFR gene that result in an overactive EGFR protein; these can be treated with EGFR inhibitors osimertinib, erlotinib
Lung_cancer
Chemical compound
potential use in cancer treatment. As a epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, oritinib targets specific enzymes involved in
Oritinib
Enzyme
lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) mutation BCR-ABL is a constitutively activated tyrosine kinase that is associated
Tyrosine_kinase
Danish healthcare company
Rybrevant (amivantamab) for the treatment of non-small-cell lung cancer (EGFR exon 20 insertion mutations) (Janssen) Talvey (talquetamab) for the treatment
Genmab
American biopharmaceutical company
patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 20 mutations. Spectrum's BTD application included data from 30 patients
Spectrum_Pharmaceuticals
Accumulation of mutations
assessing irreversible EGFR inhibitors (which inhibit growth even in cell lines with mutations in EGFR), the combination of EGFR and MET kinase inhibitors
Somatic_evolution_in_cancer
Natural regrowth of damaged liver tissue
factors EGFR and HGFR or c-Met (outside the hepatocyte). The presence of these two proteins increases the regenerative response because the HGF and EGFR act
Liver_regeneration
Medication
(L01) CI monoclonal antibodies ("-mab") Receptor tyrosine kinase ErbB: HER1/EGFR (Cetuximab Panitumumab) HER2/neu (Pertuzumab Trastuzumab (+hyaluronidase)
Elranatamab
Chemical compound
"Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR -Mutated Non–Small Cell Lung Cancer". Cancer Discovery. 12 (1):
Deruxtecan
Signaling within the same cell
Wnt pathway result in transactivation of epidermal growth factor receptor (EGFR) and other pathways, in turn contributing to proliferation of tumor cells
Autocrine_signaling
Monoclonal antibody
PD-L1-high metastatic non-small-cell lung cancer (NSCLC) who do not harbor EGFR mutations or ALK rearrangements. Tiragolumab is a fully human IgG1/kappa
Tiragolumab
Describes a new class of consumer health testing
Creatinine Ratio ✓ ✓ ✓ ✓ ✓ ✓ ✓ Chloride ✓ ✓ ✓ ✓ ✓ ✓ ✓ Creatinine ✓ ✓ ✓ ✓ ✓ ✓ ✓ eGFR ✓ ✓ ✓ ✓ ✓ ✓ Potassium*** ✓ ✓ ✓ ✓ ✓ ✓ Sodium*** ✓ ✓ ✓ ✓ ✓ ✓ Carbon Dioxide***
Direct-to-consumer blood testing
Direct-to-consumer_blood_testing
Japanese pharmaceutical company
its two major programs TAK-186 (MVC-101) in trials for the treatment of EGFR-expressing tumours and TAK-280 (MVC-280) for use in the treatment of patients
Takeda_Pharmaceutical_Company
Chronic loss of kidney function
determined and used to calculate the estimated glomerular filtration rate (eGFR). Normal eGFR is equal to or greater than 90ml/min/1.73 m2. On biopsy, the following
Diabetic_nephropathy
Type of spinal cancer
growth factor receptor-beta (PDGFR-b), epidermal growth factor receptor (EGFR), KIT (CD117) and HER2 were detected in 100%, 67%, 33% and 0% of cases, respectively
Chordoma
Monoclonal antibody
the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity. The mouse monoclonal antibody (mAb425) from which matuzumab
Matuzumab
Protein in Drosophila melanogaster
which is the major activator of their epidermal growth factor receptor (EGFR). Spitz is produced as a transmembrane protein in the endoplasmic reticulum
Spitz_(protein)
Monoclonal anti-PD-L1 antibody
progressed during or following platinum-containing chemotherapy. People with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved
Atezolizumab
Biotechnology company
studies. HTI-1511 Anti-EGFR ADC: An antibody-drug conjugate (ADC) with a strong cytotoxin, monomethyl auristatin E, designed to treat EGFR-positive tumors,
Halozyme
Cell receptor protein found in humans
or radiotherapy. In breast cancer, where EGFR inhibitors such as erlotinib are being used to inhibit the EGFR signaling pathway, IGF-1R confers resistance
Insulin-like growth factor 1 receptor
Insulin-like_growth_factor_1_receptor
Chemical compound
cysteine residue near the kinase domain of epidermal growth factor receptor (EGFR). In the US, it was given a breakthrough therapy designation in non-small
Olmutinib
Cell cycle regulation pathway
pathway can happen as a function of overexpression of upstream regulators like EGFR, activating mutations of PIK3CA, loss of function or expression of phosphatase
PI3K/AKT/mTOR_pathway
Cascade of intracellular and molecular events for transmission/amplification of signals
acts as a dimerization partner of other epidermal growth factor receptors (EGFR), constitutive activation leads to hyperproliferation and cancer. The prevalence
Signal_transduction
Medication
to surface redistribution of ERBB2 and EGFR in CDRs and that the ERBB2-dependent MAPK phosphorylation and EGFR/ERBB1 expression are both required for
Trastuzumab
Medical condition
loci. This allows assessment of other key loci in glial tumors, such as EGFR (EGFR) and TP53 copy number status. Whereas the prognostic relevance of 1p and
Oligodendroglioma
Monoclonal antibody
monoclonal antibody designed for the treatment of cancer. It is an anti-EGFR antibody that acts as an immunomodulator. The drug was developed by Genentech/Roche
Imgatuzumab
Drug for the treatment of lung carninoma
lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR. Dacomitinib has advanced to several Phase III clinical trials. In January
Dacomitinib
Antibody-drug conjugate
were evaluated in one clinical trial of 168 participants with non-squamous, EGFR wild-type non-small cell lung cancer with high c-Met protein overexpression
Telisotuzumab_vedotin
Medical condition
growth factor receptor (EGFR) pathway is commonly active in inflammatory breast cancer; this has the clinical implication that EGFR targeting therapy may
Inflammatory_breast_cancer
Protein-coding gene in the species Homo sapiens
tyrosine kinase, ACK1, that binds to multiple receptor tyrosine kinases e.g. EGFR, MERTK, AXL, HER2 and insulin receptor (IR). ACK1 also interacts with Cdc42Hs
TNK2
Protein
the capacity to activate EGFR. EGFR can be activated from a membrane-anchored growth factor as well. When TGF-α binds to EGFR it dimerizes triggering phosphorylation
TGF_alpha
Protein-coding gene in the species Homo sapiens
interacting protein 1 A transcriptional repressor that potentially regulates TNF, EGFR and PDGFA. Possibly involved in the control of smooth muscle cell proliferation
C8orf48
Pharmaceutical compound
2025). "Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid
Garsorasib
Antibody-drug conjugate
(U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC". Annals of Oncology. 31: S1189–S1190. doi:10.1016/j
Patritumab_deruxtecan
Type of inhibitor
inhibitors. The first published example of a targeted covalent drug was for the EGFR kinase. But this has now broadened to other kinases and other protein families
Targeted_covalent_inhibitors
EGFR
EGFR
EGFR
EGFR
Surname or Lastname
English
English : variant spelling of Knowles.
Boy/Male
Indian
A cowherd, Name of dynasty
Girl/Female
Australian, Danish, Finnish, German, Portuguese, Swedish
Protective; Helmet; Will-helmet; Resolute Protector
Boy/Male
Hindu, Indian
Truth; Law
Boy/Male
Hindu, Indian
Disobedient
Girl/Female
German, Teutonic
Woman Warrior; Heroine; Bold Battle
Boy/Male
Biblical
Who overthrows or destroys a multitude.
Girl/Female
Hindu, Indian, Kannada, Malayalam, Marathi, Oriya, Tamil, Telugu
Beauty; Goddess Laxmi; Goddess Durga; Fact
Girl/Female
Tamil
Girl/Female
Muslim
From the Arabic name meaning reddish
EGFR
EGFR
EGFR
EGFR
EGFR